Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051512 | 0.90 | TSHR (0.53) | TSHRCETPSRCALDH1A1FOLH1 | |
| SCHEMBL9051467 | 0.88 | TSHR (0.66) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL6572557 | 0.88 | TSHR (0.66) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL17170418 | 0.88 | TSHR (0.55) | TSHRCETPIDO1SRCPDPK1 | |
| SCHEMBL12876158 | 0.86 | TSHR (0.53) | TSHRCETPALPGALDH1A1LMNA | |
| SCHEMBL22402661 | 0.86 | TSHR (0.63) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL5850148 | 0.84 | TSHR (0.61) | TSHRCETPIDO1SRCPDPK1 | |
| SCHEMBL4641409 | 0.83 | TSHR (0.64) | TSHRCETPSRCPDPK1MTOR | |
| SCHEMBL18377837 | 0.83 | TSHR (0.59) | TSHRCETPIDO1SRCPDPK1 | |
| SCHEMBL29182982 | 0.83 | TSHR (0.59) | TSHRCETPIDO1SRCPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2024182772-A2 | MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-18 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| EP-1131327-B1 | PROSTAGLANDIN CONJUGATES FOR TREATING OR PREVENTING BONE DISEASES | MERCK FROSST CANADA INC (CA) | 2003-02-19 | — | — | EP | disclosed |
| EP-1131327-A1 | PROSTAGLANDIN CONJUGATES FOR TREATING OR PREVENTING BONE DISEASE | Merck Frosst Canada & Co. (CA) | 2001-09-12 | — | — | EP | disclosed |
| US-6121253-A | BONE GROWTH-ENHANCING PROSTAGLANDIN DERIVATIVE CONTAINING BISPHOSPHONATE GROUPS TO INHIBIT BONE RESORPTION; DRUG DELIVERY, SIDE EFFECT REDUCTION, OSTEOPOROSIS | MERCK FROSST CANADA & CO. (CA) | 2000-09-19 | — | — | US | disclosed |
| WO-2000031084-A1 | PROSTAGLANDIN CONJUGATES FOR TREATING OR PREVENTING BONE DISEASE | MERCK FROSST CANADA & CO. (CA) | 2000-06-02 | — | — | WO | disclosed |
| EP-0479813-B1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1995-09-20 | — | — | EP | disclosed |
| US-5376649-A | For bone disorders | LEIRAS OY (FI) | 1994-12-27 | — | — | US | disclosed |
| US-5227508-A | Antitumor | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0479813-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES. | HUHTAMAEKI YHTHYMAE OY (FI) | 1992-04-15 | — | — | EP | disclosed |
| WO-1990015806-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | Huhtamäki Oy (FI) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | S1PR3, S1PR1, S1PR5 | TSHR 232/4885CETP 588/4885IDO1 3464/4885 |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885IDO1 1752/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885IDO1 1752/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | TSHR 28/4885CETP 1999/4885IDO1 3343/4885 |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885IDO1 1752/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885IDO1 1752/4885 |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | TSHR 2816/4885CETP 2787/4885IDO1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.